The UCSF Helen Diller Family Comprehensive Cancer Center is the only center in the Bay Area to receive the prestigious designation of "comprehensive" from the National Cancer Institute. We treat all forms of cancer. With new facilities, expanded programs and innovative research, we help cancer patients live longer and fuller lives. The center ranks first in California and sixth nationwide in National Cancer Institute research grants, and is home to pioneers in research into genetic, cellular and immune system causes and responses to cancer.
Latest Videos |view all videos
Bonnie Joe, MD explains the differences between screening and diagnostic mammography, shows evidence for screening, answers common questions about radiation risk and false positives and discusses digital breast tomosynthesis, also known as 3D mammography.
Bonnie Joe, MD, PhD, discusses how breast MRI is performed, common indications for breat MRI and advanced methods for biopsy and pre-surgical localization of tumors.
Oncologist David Oh speaks at the October 2017 Bay Area Breast Cancer Forum about key developments in immunotherapy like immune checkpoint inhibitors and T-cell therapies, plus its use in experimental approaches to breast cancer treatment.
Discover the surprising way a simple surgery can vastly improve quality of life for head and neck cancer patients after radiation treatment. How? By moving the submandibular gland out of the way of the most intense radiation to prevent xerostomia.
Take a deep dive into therapy options for newly diagnosed myeloma patients: whether three drugs are better than two, the case for lenalidomide maintenance therapy, the many improvements in induction treatment, the future of immunotherapy, and more.
Immunologist Michael Campbell and breast cancer surgeon Laura Esserman speak at the April 2017 Bay Area Breast Cancer Forum about the human biome, how it’s being studied and how it relates to breast cancer prevention and treatment.
Follow the journey of a UCSF patient with early-stage, high-risk lung cancer, from history to treatment and prognosis, including how surgeons chose to do a robotic assisted VATS lobectomy and an analysis of how well chemo is likely to work for her.
A June 2017 Bay Area Breast Cancer Forum discussion of updates from the ASCO annual meeting, covering PARP inhibitors, germline BRCA mutations, HER2-positive cancer, patient-reported outcomes, immunotherapy and more. Moderator: Dr. Hope Rugo